Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States by Bradley J. Monk, Sophie van Mens, Oliver Hale, Jennifer Boer, Frank van Hees, Shilpi Swami, Dominic Muston, Cumhur Tekin, Steve Keefe, Matthew Monberg

Get full text